This page shows the latest thyroid cancer news and features for those working in and with pharma, biotech and healthcare.
According to lawyers working on behalf of the plaintiffs, the replacement caused patients to experience severe side effects, including hair loss, memory loss, weight gain and in some cases, thyroid cancer. ... Despite the company’s claims, French group
metastatic RET-mutant medullary thyroid cancer and advanced or metastatic RET fusion-positive thyroid cancer. ... Although RET activating fusions and mutations are only observed in a small number of cancer patients – around 1-2% in NSCLC and 10-20% in
Administration (FDA) for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC), RET mutation-positive medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer. ... Although RET activating fusions and mutations are only
Exelixis previously attempted to tackle prostate cancer with cabozantinib back in 2014, but the drug was unable to show any survival benefit on its own. ... Cabozantinib, a c-MET and VEGFR2 inhibitor, is already approved under the brand name Cometriq as
Another promising candidate Lilly gained from the Loxo takeover is LOXO-292, which is currently being studied in phase 3 trials for non-small cell lung cancer and medullary thyroid cancer.
with BLU-667 for at least 24 weeks, and 49% across all patients with that type of cancer. ... Existing treatment of medullary and papillary thyroid cancer with multi-kinase inhibitors is limited by frequent dose modifications or interruptions due to
More from news
Approximately 9 fully matching, plus 53 partially matching documents found.
Ipsen paid $200m upfront for the rights (ex-North America &Japan) to commercialise Cometriq for medullary thyroid cancer and other indications. ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal
In a display of its global ambition, EATRIS is joining with Cancer Research UK to bring representatives of the US's National Cancer Institute to a workshop in Brussels in October ... The first one we initiated in this matchmaking process was a bio-marker
As ASCO commences the company's VP of oncology talks to PMLiVE about its pipeline prospects in cancer. ... The company is building on its recent oncology launches of Caprelsa (vandetanib) for medullary thyroid cancer - approved in Europe in 2012 - and
In 2012 these drugs generated $289.6m in revenue for Onyx. Included in the Onyx clinical pipeline are sorafenib (in phase III for thyroid cancer) also partnered with Bayer and carfilzomib, ... This protracted process is indicative of the now “holy
III, this time for thyroid cancer. ... The company is also still very much in launch mode with its first cancer drug Halaven, which has been brought to most of the major European markets.
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...